Adaptive Biotechnologies Corp (NASDAQ: ADPT) kicked off on Friday, up 14.89% from the previous trading day, before settling in for the closing price of $2.62. Over the past 52 weeks, ADPT has traded in a range of $2.53-$9.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.46% over the past five years. While this was happening, its average annual earnings per share was recorded 16.03%. With a float of $138.51 million, this company’s outstanding shares have now reached $145.08 million.
Let’s look at the performance matrix of the company that is accounted for 709 employees.
Adaptive Biotechnologies Corp (ADPT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adaptive Biotechnologies Corp is 4.54%, while institutional ownership is 95.41%. The most recent insider transaction that took place on Mar 05 ’24, was worth 167,007. In this transaction CEO and Chairman of this company sold 48,673 shares at a rate of $3.43, taking the stock ownership to the 2,576,701 shares. Before that another transaction happened on Mar 05 ’24, when Company’s President sold 39,070 for $3.47, making the entire transaction worth $135,764. This insider now owns 472,754 shares in total.
Adaptive Biotechnologies Corp (ADPT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 21.60% during the next five years compared to -32.91% drop over the previous five years of trading.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Take a look at Adaptive Biotechnologies Corp’s (ADPT) current performance indicators. Last quarter, stock had a quick ratio of 4.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its 5-day average volume 2.32 million, a positive change from its year-to-date volume of 1.54 million. As of the previous 9 days, the stock’s Stochastic %D was 35.90%. Additionally, its Average True Range was 0.28.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 16.22%, which indicates a significant decrease from 59.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 115.45% in the past 14 days, which was higher than the 77.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.47, while its 200-day Moving Average is $4.94. Nevertheless, the first resistance level for the watch stands at $3.22 in the near term. At $3.44, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.77. If the price goes on to break the first support level at $2.67, it is likely to go to the next support level at $2.34. Assuming the price breaks the second support level, the third support level stands at $2.12.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
The company with the Market Capitalisation of 436.72 million has total of 145,092K Shares Outstanding. Its annual sales at the moment are 170,280 K in contrast with the sum of -225,250 K annual income. Company’s last quarter sales were recorded 45,780 K and last quarter income was -69,440 K.
